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Introduction 
 Renal cell carcinoma (RCC) is the most common 
cancer associated with the kidney.  RCC accounts for 
approximately 3% of  all adult malignancies with the 
incidence increasing by almost 2% per year. 1,2  Radical 
nephrectomy is the standard of  treatment for patients 
with localized disease; however approximately 30% of  
patients present with metastasis.2   
 The use of  radiation therapy is most often limited 
to post-operative cases when residual tumor is 
identified or for symptomatic relief  of  metastatic 
disease.  Definitive radiation treatment is not 
commonly indicated due to the low tolerance to 
radiation of  surrounding abdominal structures such as 
the small bowel, ipsilateral kidney, and spinal cord.  
For patients diagnosed with left-sided RCC, the main 
dose limiting structure is the small bowel.  The 
following case study will focus on avoiding bowel 
toxicity with the use of  post-operative radiation 
therapy for the treatment of  a Stage III left-sided renal 
cell carcinoma.     
     
 
Case Description 
 This case involves a 47-year-old white male who 
presented with left flank pain, hematuria, and a topical 
abdominal mass.  Computed tomography (CT) revealed 
a large mass in the left kidney.  The patient underwent 
a left sided nephrectomy which demonstrated clear 
renal cell carcinoma with sarcomatoid and rhabdoid 
differentiation.  Surgical margins were clear with the 
exception of  evidence of  cancerous cells within the 
actual renal vein.  The patient was staged as T3b, NX, 
M0.  
 Radiation therapy was recommended. The patient 
initially underwent CT simulation in the supine position 
(Figure 1). A significant amount of  bowel was noted in 
the proposed treatment plan. The patient was then 
repositioned  and a CT simulation in the right lateral 
decubitus position was performed (Figure 2).  
 The prescription dictated a dose of  4500cGy be 
delivered at 180cGy/fraction for 25 fractions. A boost 
field was planned to a dose of  900cGy in 5 fractions for 
a cumulative dose of  5400cGy. Both fields utilized 23 
MV photons.  
  
   
Bowel Toxicity 
  Normal tissue tolerance doses to radiation often 
limit the curability of  a malignancy. A tumor lethal dose 
of  radiation cannot be delivered when a critical 
structure, such as the small bowel, is included in the 
treatment field. 
 Small bowel radiation toxicity is characterized by 
mucosal inflammation and breakdown. Chronic injury 
includes the development of  progressive vascular 
stenosis and intestinal wall fibrosis.3 Acute and chronic 
toxicities associated with irradiation of  the small bowel 
are listed in Table 1.3,4  
 The two most important factors influencing 
radiation toxicity to the small bowel are the total dose 
of  radiation received and the volume of  bowel in the 
field. Complication rates for critical structures are 
identified in terms of  TD5/5. This represents the Tissue 
Dose associated with a 5% injury rate within 5 years of  
radiation treatment. The TD5/5 doses for the small bowel 
are 4500cGy for approximately 400cm2 of  bowel and 
5000cGy when 100cm2 of  bowel is included in the 
treatment field.5 This correlation shows the importance 
of  conformal radiation techniques.  
Acute Effects  
(6-18 months post RT) 
Chronic  Effects 
(18 months- 5 years post RT) 
Diarrhea Bowl Obstruction 
Colicky Abdominal Pain Fistula Formation 
Nausea Perforation 
Vomiting Hemorrhage 
Figure 1. Supine computer plan.  
Figure 2. Lt. Lat. Decubitus computer plan.  
Dose Comparison 
On the Supine computer plan, a large volume of  small bowel 
is receiving 80% to 102% of  the prescribed dose. This would 
well exceed the TD5/5 limitation.  
 
According to the Decubitus plan, the volume of  small bowel 
included in the field was much less than the supine and the 
dose was limited to approximately 80% or 4320cGy. 
Conclusion 
 The standard of  care for RCC is surgery; however,  
with modern treatment techniques and adaptation of  
dose and treatment volume, complication rates are 
considerably lower than 5-10% in daily practice and 
comparable to major abdominal surgery alone.3 
 Clinical trials including systemic biological agents 
are underway for the treatment of  RCC.1 These 
innovative approaches may aid in reducing the need for 
radiation therapy for advanced RCC and the possible 
toxicities associated with it to the small bowel.  
Table 1.3,4  Possible side effects associated with radiation to the abdomen 
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